{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:25:10Z","timestamp":1781886310560,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite recent advances and an improved treatment paradigm, the prognosis in patients with advanced non-small-cell lung cancer (NSCLC) remains poor. Novel endpoints to evaluate antitumor activity are needed to expedite safe and effective drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective pooled analysis of 10,495 patients with NSCLC using radiological tumor measurements across 22 randomized clinical trials fit to a regression-growth model to derive the g value. We evaluated the g value across both type and line of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The g value is inversely associated with survival. Patients receiving targeted therapy had lower g values than patients receiving immune checkpoint inhibitors or chemotherapy. Additionally, patients receiving front-line treatment had a lower g value than patients receiving later line treatment. A lower g value was associated with a higher median overall survival (OS) and a longer median progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The g value, as a volumetric measurement of tumor growth rate, may provide an additional or supplementary approach to assess the potential clinical activity of an agent. Prospective studies are needed to further assess the association of the g value derived from early tumor measurements with long-term outcomes in patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag009","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:43:00Z","timestamp":1768480980000},"source":"Crossref","is-referenced-by-count":3,"title":["An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3777","authenticated-orcid":false,"given":"Justin N","family":"Malinou","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Fan","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Gong","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Larkins","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026030406384999600_oyag009-B1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/djr062","article-title":"Accelerated approval of oncology products: the food and drug administration experience, JNCI","volume":"103","author":"Johnson","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026030406384999600_oyag009-B2","author":"Cancer Accelerated Approvals"},{"key":"2026030406384999600_oyag009-B3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"2026030406384999600_oyag009-B4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(16)30633-7","article-title":"Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis","volume":"18","author":"Wilkerson","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026030406384999600_oyag009-B5","first-page":"139","author":"Yeh"},{"key":"2026030406384999600_oyag009-B6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B7","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026030406384999600_oyag009-B10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B11","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026030406384999600_oyag009-B13","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026030406384999600_oyag009-B15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2026030406384999600_oyag009-B17","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B19","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026030406384999600_oyag009-B20","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026030406384999600_oyag009-B21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B23","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030406384999600_oyag009-B24","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2026030406384999600_oyag009-B25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026030406384999600_oyag009-B26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2026030406384999600_oyag009-B27","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"2026030406384999600_oyag009-B28","first-page":"100637","article-title":"Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced\/metastatic non-small cell lung cancer","volume":"33","author":"Bazhenova","year":"2022","journal-title":"Cancer Treat Res Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag009\/66436589\/oyag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag009\/66436589\/oyag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag009\/66436589\/oyag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:38:59Z","timestamp":1772624339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag009\/8428097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag009","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,16]]},"article-number":"oyag009"}}